Navamedic ASA · OSL:NAVA
Navamedic ASA — Q4 2021 Earnings Presentation
25 slides from Navamedic ASA's earnings presentation, 2022
Slide 1: Fourth quarter results 2021
Q4 2021 Fourth quarter results 2021 Navamedic ASA Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO 1
Slide 2: Highlights
Highlights Revenue growth exceeding target significantly; Specialty Pharma key growth driver Operations and sales Accelerated growth for Mysimba® and extended exclusive distribution rights in the Nordics REVENUE GROSS MARGIN EBITDA Q4 90.2 MNOK 41.9% 7.6 MNOK Solid growth in Consumer Health, Launch
Slide 3: Navamedic in brief
Navamedic in brief Nordic pharma company targeting growth in Northern Europe A reliable supplier of high- Presence in all Nordic ~ 30 professionals with Ambitious growth strategy, quality consumer health, countries, Baltics and strong local competence in high-potential pipeline and medical nutrition
Slide 4: Ambition of building a leading Nordic pharma company
Navamedic in brief Ambition of building a leading Nordic pharma company targeting growth in Northern Europe OUR MID-TERM TARGET 1 2 3 20% annual organic STRENGTHEN THE SECURE AND GROWTH THROUGH growth with a mid-term CORE INCREASE THE M&A ambition of building VALUE THROUGH a 500 MNOK company with a
Slide 5: Key portfolio developments
Key portfolio developments Solid growth in key product areas in 2021 MEDICAL CONSUMER BRANDED SPECIALTY NUTRITION HEALTH GENERICS PHARMA FY 2021 revenue (YoY growth): 51.9 (2%) FY 2021 revenue (YoY growth): 43.7 (31%) FY 2021 revenue (YoY growth): 70.6 (6%) FY 2021 revenue (YoY growth): 112.3 (90%)
Slide 6: Specialty Pharma: Strong development for Mysimba in Q4
Specialty Pharma Strong development for Mysimba® in Q4 Q4 2021 REVENUE 42.8 MNOK GROWTH DRIVERS • Long-term strong (Q4 2020: 17.7 MNOK) development of obesity THE ONLY ORAL category MEDICINE FOR • Mysimba® growth TREATMENT OF OBESITY exceptionally strong in Q4 WITH DUAL MODE OF 112.3 (90%) 2021 ACTI
Slide 7: Rapid adoption of Mysimba
Specialty Pharma Rapid adoption of Mysimba® MARKET MARKET STRONG SALES KNOWLEDGE BASE SIZE SHARE DEVELOPMENT AND SUPPORT PROGRAM Estimated addressable market in the Nordic countries (number of people)* Current market share in the Nordics and selected countries (percentage)* 208% increase from Q4 202
Slide 8: Medical Nutrition: Good development for new product ranges
Medical Nutrition Good development for new product ranges Q4 2021 REVENUE GROWTH DRIVERS 13.3 MNOK • New products for PKU, the (Q4 2020: 13.2 MNOK) most important part of the medical nutrition area • Slight slowdown in growth 51.9 (2%) due to more competition from pharma and medical FY 2021 revenue
Slide 9: Consumer Health: Launch of new and unique products contribute to growth
Consumer Health Launch of new and unique products contribute to growth Q4 2021 REVENUE 12.6 MNOK GROWTH DRIVERS (Q4 2020: 11.8 MNOK) • Strong performance for ThermaCare® and GeloRevoice® • Alflorex® with solid growth 43.7 (31%) during the quarter FY 2021 revenue (YoY growth): 9
Slide 10: Gastro: Launch of SmectaGo and Forlax
Gastro Launch of SmectaGo® and Forlax® in segment with unmet medical and consumer needs Further category development through product launches in Top three causes of Q1 2022: diarrhea among adults: • Nearly half of the population suffer from gastro related problems each year • SmectaGo® launched in t
Slide 11: Branded Generics: Antibiotics portfolio growing rapidly
Branded Generics Antibiotics portfolio growing rapidly Q4 2021 REVENUE GROWTH DRIVERS 21.3 MNOK • Strong performance for (Q4 2020: 12.6 MNOK) the antibiotic portfolio with several new tenders won • Imdur® back to growth in Q4 from low levels due to 70.6 (6%) previous out-of-stock situation FY 2021 r
Slide 12: Financials
FINANCIALS @ Navamedic
Slide 13: Key consolidated profit and loss figures
Financials Key consolidated profit and loss figures In Q4 2021, revenues grew by 63% compared to the same quarter last year, contributing to a full year (in NOK '1000) Q4 2021 Q4 2020 FY 2021 FY 2020 revenue growth of 32.7% Operating revenues 90 160 55 302 278 439 209 877 Gross profit 37 797 22 324
Slide 14: Assets
Financials Assets The change in Goodwill is due to currency effect (in NOK '1000) 31.12.2021 31.12.2020 Increase in Other intangible assets is due to Goodwill 61 031 64 472 the acquisition/booking of the marketing Deferred tax assets 9 168 9 168 authorizations related to the antibiotics portfolio in
Slide 15: Equity and liabilities
Financials Equity and liabilities (in NOK '1000) 31.12.2021 31.12.2020 Equity ratio of 45.8%. Total equity 151 237 129 486 Non-current license liabilities 8 171 3 343 Increase in Equity is mainly due to Loans and borrowings 38 980 20 870 share premium from ACS share issue in Q1 Non-current right of
Slide 16: Cash flow Group – total operations
Financials Cash flow Group – total operations The cash flow from Operating (in NOK '1000) Q4 2021 Q4 2020 FY 2021 FY 2020 Activities is mainly the result of Net Net cash flow from operating activities 11 284 14 836 -1 300 -3 180 profit coupled with changes in net working capital Net cash flow from i
Slide 17: Summary & Outlook
SUMMARY & OUTLOOK 17 @ Navamedic
Slide 18: Summary and outlook
Navamedic ASA Summary and outlook Building a leading Nordic pharma company targeting growth in Northern Europe In Q4 2021, we have • Continued to strengthen the core by driving underlying growth in the existing portfolio • Increased revenues by 63% Y-o-Y • Continued our push for growth of key produc
Slide 19: Q&A
Q&A @ Navamedic
Slide 20: Thank you for your attention!
Thank you for your attention! Navamedic’s annual report for 2021 be available on 29th of April 2022 Navamedic’s Q1 2022 presentation will be on 10 of May 2022 th 20
Slide 21: Appendix
APPENDIX @ Navamedic
Slide 22: Condensed consolidated statement of comprehensive income
Navamedic ASA Condensed consolidated statement of comprehensive income (in NOK '1000) Q4 2021 Q4 2020 FY 2021 FY 2020 Operating revenues 90 160 55 302 278 439 209 877 Total revenue 90 160 55 302 278 439 209 877 Cost of materials -52 363 -32 978 -166 695 -139 538 Gross profit 37 797 22 324 111 744 70
Slide 23: Condensed consolidated statement of cash flows
Navamedic ASA Condensed consolidated statement of cash flows (in NOK '1000) Q4 2021 Q4 2020 FY 2021 FY 2020 Cash flow from operating activities Profit before tax 1 979 -4 561 2 358 -16 596 Adjusted for: Depreciation, amortization and impairment 2 564 919 6 716 3 659 Financial income / expenses witho
Slide 24: Basis for preparation and Definitions of Alternative Performance Measures
Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres
Slide 25: Copyright and disclaimer
Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any